0001104659-23-075407.txt : 20230627
0001104659-23-075407.hdr.sgml : 20230627
20230627211546
ACCESSION NUMBER: 0001104659-23-075407
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230627
FILED AS OF DATE: 20230627
DATE AS OF CHANGE: 20230627
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rawcliffe Adrian
CENTRAL INDEX KEY: 0001555851
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37368
FILM NUMBER: 231048991
MAIL ADDRESS:
STREET 1: 440 SOUTH BROAD STREET, UNIT 1906
CITY: PHILADELPHIA
STATE: PA
ZIP: 19146
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptimmune Therapeutics PLC
CENTRAL INDEX KEY: 0001621227
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 JUBILEE AVENUE
STREET 2: MILTON PARK
CITY: ABINGDON, OXFORDSHIRE
STATE: X0
ZIP: OX14 4RX
BUSINESS PHONE: 44 1235 430000
MAIL ADDRESS:
STREET 1: 60 JUBILEE AVENUE
STREET 2: MILTON PARK
CITY: ABINGDON, OXFORDSHIRE
STATE: X0
ZIP: OX14 4RX
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptimmune Ltd
DATE OF NAME CHANGE: 20141001
4
1
tm2317417-5_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-06-27
0
0001621227
Adaptimmune Therapeutics PLC
ADAP
0001555851
Rawcliffe Adrian
C/O ADAPTIMMUNE THERAPEUTICS PLC,
60 JUBILEE AVENUE, MILTON PARK
ABINGDON
X0
OX14 4RX
UNITED KINGDOM
1
1
0
0
Chief Executive Officer
0
American Depositary Shares representing Ordinary Shares
2023-06-27
4
S
0
2333
0.92
D
3519
D
Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
The price reported in Column 4 is the sale price per ADS.
The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 155,103 ADSs and RSU-style options and other options covering an aggregate of 27,496,302 ordinary shares of the Issuer.
/s/ Adrian George Rawcliffe
2023-06-27